Please assess the completion status of the following clinical trial:

Trial Title: Javelin BRCA/ATM: Avelumab Plus Talazoparib in Patients With BRCA or ATM Mutant Solid Tumors

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* BRCA1, BRCA2 and/or ATM gene defect.~* Histological diagnosis of locally advanced (primary or recurrent) or metastatic solid tumors that are not amenable for treatment with curative intent~* Availability a tumor tissue sample from a diagnostic biopsy/surgery or a metastatic tumor biopsy.~* Progressive disease at study enrollment.~* Minimum age 18 years (in Japan, minimum age 20 years).~* ECOG performance status 0 or 1.~* Adequate bone marrow, renal and liver function.~* For childbearing female patients, negative serum or urine pregnancy test at screening~* Signed and dated informed consent document.~Exclusion Criteria:~* Prior anti-cancer therapy or radiation therapy within 2 weeks prior to enrolment. Palliative radiotherapy to metastatic lesion(s) permitted providing that it has been completed at least 2 days prior to enrolment and no significant toxicity are expected.~* Major surgery within 4 weeks prior to study enrollment.~* Current use of immunosuppressive medication at the time of study enrollment.~* Known prior severe hypersensitivity to investigational products or any component in their formulations~* Known history of immune-mediated colitis, inflammatory bowel disease, pneumonitis, pulmonary fibrosis.~* Active or prior autoimmune disease that might deteriorate when receiving an immunostimulatory agent.~* Prior organ transplantation including allogenic stem-cell transplantation.~* Administration of live attenuated vaccines within 4 weeks of study enrollment.~* Diagnosis of myelodysplastic syndrome.~* Known symptomatic brain metastases requiring steroids.~* Persisting toxicity related to prior therapy Grade \>1.~* Known history of HIV or AIDS.~* Positive HBV or HCV test indicating acute or chronic infection.~* Active infection requiring systemic therapy.~* Clinically significant (active) cardiovascular disease: cerebral vascular accident/stroke or myocardial infarction within 6 months prior to study enrollment; unstable angina, congestive heart failure or a serious cardiac arrhythmia requiring medication.~* Diagnosis of any other malignancy within 2 years prior to study enrollment, except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ of the breast, bladder, or cervix, or low-grade prostate cancer or other early-stage low-risk cancers.~* Pregnant or breastfeeding female patients; female or male patients who are able to have children who are unable or unwilling to use contraception as outlined in the protocol.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Combination of avelumab and talazoparib (Type: EXPERIMENTAL): Single arm open label

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy